New oral drug kamlanoflast enters human testing for ALS
Disease control
Not yet recruiting
This study tests an oral drug called Kamlanoflast in 40 adults with ALS. The goal is to see if it is safe, tolerable, and can reduce inflammation or slow disease progression over 24 weeks. Participants must be 18-75 years old, diagnosed with ALS within the last 3 years, and have …
Phase: PHASE1, PHASE2 • Sponsor: Inflammasome Therapeutics • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC